On Jun. 10, 2019, Genentech drug Polivy (polatuzumab vedotin-piiq) announced the U.S. Food and Drug Administration (FDA) had granted accelerated approval to Polivy (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies.